Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: a retrospective cohort study

Fig. 1

Longitudinal Trend of Post-TNF Inhibitor Maintenance Treatment Lines: Mono vs. Combination Therapy. Each square matrix is vertically arranged in chronological order of maintenance therapy lines after tumor necrosis factor (TNF) inhibitor discontinuation and horizontally by individual maintenance therapy regimen, with color coding. Blue is methotrexate monotherapy; orange is methotrexate and tacrolimus combination therapy. The numbers of TNF inhibitor discontinuations per subsequent maintenance therapy regimen in the square matrices and those of subsequent relapses requiring resumption of biological disease-modifying antirheumatic drugs (bDMARD) or Janus kinase inhibitors (JAKi) in the black parallelograms are displayed

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us